The Clinical Observation of Paclitaxel or Vinorelbine Combined with Cisplatin in Treatment of Advanced Patients with Non-small Cell Lung Cancer

Objective:To estimate the efficacy,taxicity and side effects of the two combinations of paclitaxel cisplatin and vinorebine cisplatin in the treatment of advanced patients with non-small cell lung cancer (NSCLC).Methods:58 advanced patients with NSCLC diagnosed by pathology were enrolled into two groups randomly ,each group have 28 patients.The group A with 28 patients received paclitaxel 150 mg/m~2 and cisplatin 80 mg/m~2 in the first day; The group B with antother 30 patients received vinorelbine 25 mg/m~2 on day1.8 and cisplatin 80 mg/m~2 in the first day.Both regiments had 21 day cycle, three weeks repeated and the efficacy was estimated after 3 periods. Results: the efficacy with group A and B were 50.0%(14/28) and 46.7%(14/30), respectively.There was no significant difference(P0. 05) between two groups from the view of accounting. The median ailment development time were 4.8 and 4.1 months for group A and B, respectively and there were some accounting difference(P0.05).The median survival time were 12 and 11.5 months, no significant difference appeared(P0.05).Finally the 1 year survival time were 45. 6% for group A and 43.5% for group B and there were also no significant difference(P0.05). The Ⅲ-Ⅳthromasthenia with group A was little higher than that of group B, but the lII-IV leucopenino and alopecia with group A were apparently lower than that of group B. Conclusion:There were no significant difference with group A and B on efficacy median survival time and 1-year survival time, but there were little advantage with group A on median ailment development time.